Sex-specific immunization for sexually transmitted infections such as human papillomavirus: Insights from mathematical models

PLoS Medicine

Volumn 8, Issue 12, 2011, Pages

  Bogaards, Johannes A ^a,b   Kretzschmar, Mirjam ^b,c   Xiridou, Maria ^b   Meijer, Chris J L M ^a   Berkhof, Johannes ^a   Wallinga, Jacco ^b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; MALE; MATHEMATICAL MODEL; PREVALENCE; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; VERRUCA VULGARIS; VIRUS TRANSMISSION; WART VIRUS; DISEASE TRANSMISSION; METHODOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PATHOPHYSIOLOGY; THEORETICAL MODEL; UTERINE CERVIX TUMOR; VIROLOGY;

FEMALE; HUMANS; IMMUNIZATION; MALE; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEX FACTORS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 84855163224     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001147     Document Type: Article

References (55)

1. Hethcote HW, Yorke JA, (1984) Gonorrhea: transmission dynamics and control. Lecture notes in biomathematics 56 Berlin Springer-Verlag Available: http://www.math.uiowa.edu/ftp/hethcote/lnb56.pdf. Accessed 12 August 2011.
2. Kretzschmar M, van Duynhoven YT, Severijnen AJ, (1996) Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. Am J Epidemiol 144: 306-317.
3. Gray RT, Beagley KW, Timms P, Wilson DP, (2009) Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 199: 1680-1688.
4. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, et al. (2006) The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 3: e262 doi:10.1371/journal.pmed.0030262.
5. Wilson DP, Coplan PM, Wainberg MA, Blower SM, (2008) The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A 105: 9835-9840.
6. Cox AP, Foss AM, Shafer LA, Nsubuga RN, Vickerman P, et al. (2011) Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda. Sex Transm Infect E-pub ahead of print. doi:10.1136/sti.2010.046227.
7. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM, (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
8. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S, (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124: 1626-1636.
9. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, et al. (2009) Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 62: 870-878.
10. Parkin DM, Bray F, (2006) Chapter 2: the burden of HPV-related cancers. Vaccine 24 (Suppl 3): S11-S25.
11. Ault KA, Future II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861-1868.
12. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
13. Palefsky JM, (2010) Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 46 (Suppl 4): S12-S19.
14. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, et al. (2011) Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11: 39-44.
15. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A, (2007) European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogential warts. Sex Transm Infect 76: 162-168.
16. Advisory Committee on Immunization Practices (2009) Summary report. June 24-26, 2009. Atlanta, Georgia Atlanta (Georgia) Centers for Disease Control and Prevention Available: http://www.cdc.gov/vaccines/recs/acip/downloads/min-archive/min-jun09.pdf. Accessed 21 November 2011.
17. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, et al. (2011) The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 29: 9112-9122.
18. Kim JJ, Goldie SJ, (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339: b3884.
19. Elbasha EH, Dasbach EJ, (2010) Impact of vaccinating boys and men against HPV in the United States. Vaccine 28: 6858-6867.
20. Jit M, Choi YH, Edmunds WJ, (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769.
21. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC, (2011) Incremental impact of adding boys to current human papillomavirus vaccination programs: the role of herd immunity. J Infect Dis 204: 372-376.
22. Centers for Disease Control and Prevention (2010) National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep 59: 1018-1023.
23. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al. (2010) Proof-of-principle: efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica [abstract]. 26th International Papillomavirus Conference; 3-8 July 2010; Montreal, Canada. Available: http://www.hpv2010.org/main/index.php?option=com_conference&view=presentation&id=1754&conference=1&Itemid=103. Accessed 14 November 2011.
24. van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PA, et al. (2011) Vaccinatiegraad rijksvaccinatieprogramma Nederland Bilthoven Rijksinstituut voor Volksgezondheid en Milieu Available: http://www.rivm.nl/bibliotheek/rapporten/210021014.pdf. Accessed 21 November 2011.
25. Anderson RM, May RM, (1991) Infectious diseases of humans: dynamics and control Oxford Oxford University Press.
26. Bogaards JA, Xiridou M, Coupé VM, Meijer CJ, Wallinga J, et al. (2010) Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 171: 817-825.
27. Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, et al. (2011) Long-term impact of HPV vaccination on infection rates, cervical abnormalities and cancer incidence. Epidemiology 22: 505-515.
28. Handcock MS, Jones JH, (2006) Interval estimates for epidemic thresholds in two-sex network models. Theor Popul Biol 70: 125-134.
29. Garnett GP, Kim JJ, French K, Goldie SJ, (2006) Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 (Suppl 3): S178-S186.
30. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, et al. (2011) Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377: 932-940.
31. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, et al. (2006) Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly diskaryotic smear. Cancer Epidemiol Biomarkers Prev 15: 1268-1273.
32. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, et al. (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
33. Coupé VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ, (2008) Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98: 646-651.
34. Diekmann O, Heesterbeek JA, (2000) Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. Wiley Series in mathematical and computational biology Chichester (United Kingdom) Wiley & Sons.
35. Elbasha EH, (2008) Global stability of equilibria in a two-sex HPV vaccination model. Bull Math Biol 70: 894-909.
36. Brown V, White KA, (2010) The HPV vaccination strategy: could male vaccination have a significant impact? Comput Math Methods Med 11: 223-227.
37. Wallinga J, van Boven M, Lipsitch M, (2010) Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci U S A 107: 923-928.
38. Allen JD, Coronado GD, Williams RS, Glenn B, Escoffery C, et al. (2010) A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptance. Vaccine 28: 4027-4037.
39. Castle PE, Scarinci I, (2009) Should HPV vaccine be given to men? BMJ 339: b4127.
40. Hull SC, Caplan AL, (2009) The case for vaccinating boys against human papillomavirus. Public Health Genomics 12: 362-367.
41. Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, et al. (2011) EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer 128: 2765-2774.
42. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, et al. (2010) The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 15: pii: 19730.
43. Williams JR, Nokes DJ, Medley GF, Anderson RM, (1996) The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 116: 71-89.
44. Kretzschmar M, de Wit GA, Smits LJ, van de Laar MJ, (2002) Vaccination against hepatitis B in low endemic countries. Epidemiol Infect 128: 229-244.
45. Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, et al. (2005) Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 97: 896-905.
46. Kim JJ, (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10: 845-852.
47. Hernandez BY, Wilkens LR, Thompson PJ, Shvetsov YB, Goodman MT, et al. (2010) Acceptability of human papillomavirus vaccination among adult men. Hum Vaccin 6: 467-475.
48. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR, (2006) Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194: 1044-1057.
49. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, et al. (1996) The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174: 927-936.
50. Hernandez BY, Wilkens LR, Zhu X, McDuffie K, Thompson P, et al. (2008) Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 14: 888-894.
51. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH, (2010) Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 10: 862-874.
52. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, et al. (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26: 4080-4093.
53. Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, et al. (2011) Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis 52: 641-645.
54. Chen FH, (2006) The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 20: 1551-1553.
55. Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, et al. (2007) The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 21: 845-850.